Download MendeleyUbc9 sumoylation regulates SUMO target discrimination.
Knipscheer, P., Flotho, A., Klug, H., Olsen, J.V., van Dijk, W.J., Fish, A., Johnson, E.S., Mann, M., Sixma, T.K., Pichler, A.(2008) Mol Cell 31: 371-382
- PubMed: 18691969
- DOI: https://doi.org/10.1016/j.molcel.2008.05.022
- Primary Citation of Related Structures:
2VRR - PubMed Abstract:
Posttranslational modification with small ubiquitin-related modifier, SUMO, is a widespread mechanism for rapid and reversible changes in protein function. Considering the large number of known targets, the number of enzymes involved in modification seems surprisingly low: a single E1, a single E2, and a few distinct E3 ligases. Here we show that autosumoylation of the mammalian E2-conjugating enzyme Ubc9 at Lys14 regulates target discrimination. While not altering its activity toward HDAC4, E2-25K, PML, or TDG, sumoylation of Ubc9 impairs its activity on RanGAP1 and strongly activates sumoylation of the transcriptional regulator Sp100. Enhancement depends on a SUMO-interacting motif (SIM) in Sp100 that creates an additional interface with the SUMO conjugated to the E2, a mechanism distinct from Ubc9 approximately SUMO thioester recruitment. The crystal structure of sumoylated Ubc9 demonstrates how the newly created binding interface can provide a gain in affinity otherwise provided by E3 ligases.
Organizational Affiliation:
The Netherlands Cancer Institute and Center for Biomedical Genetics, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
